title: Evaluation of central precocious puberty treatment with GnRH analogue at the Triangulo Mineiro Federal University (UFTM).
abstract: OBJECTIVE
  To report our experience of treating central precocious puberty (CPP) with a GnRH analogue with respect to the final heights (FH) attained in patients who completed treatment.
  
  
  METHODS
  Among 105 records of children diagnosed with precocious puberty, 62 cases (54 girls and 8 boys), who were treated with leuprolide acetate/3.75 mg/monthly, were selected, and divided into 4 groups: group 1 (G1), 25 girls who attained FH; group 2 (G2), 18 girls who completed treatment but did not reach FH; group 3 (G3), 11 girls still under treatment; and group 4 (G4), 8 boys, 5 of which attained FH. Treatment was concluded at a bone age of 12 years, and follow-up continued until FH was achieved.
  
  
  RESULTS
  In both G1 and G2 groups, height standard deviation score (SDS), weight-SDS and percentile of body mass index (PBMI) did not show intra/intergroup differences at the beginning and at interruption of treatment, but when added, G1+G2, height-SDS and weight-SDS differed significantly (p = 0.002 and 0.0001, respectively). In G1, 19 of 25 cases attained TH, and average height gain was 16.7 cm (7.7- 27.1); there was significant difference between FH and prediction of FH at the start (PFH at start) (p = 0.0001), as well as between PFH at interruption vs TH and vs FH (p = 0.007) with FH higher than TH (p = 0.004). Significant correlation was identified between FH and height gain after treatment.
  
  
  CONCLUSIONS
  As shown by some studies, GnRH analogue treatment was effective in children with CPP reaching FH near the genetic target.
authors.affiliation: Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brasil.
authors.forename: Maria de Fátima
authors.initials: Mde F
authors.lastname: Borges
authors.affiliation: Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brasil.
authors.forename: Priscila de Melo
authors.initials: Pde M
authors.lastname: Franciscon
authors.affiliation: Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brasil.
authors.forename: Thamy Contursi
authors.initials: TC
authors.lastname: Cambraia
authors.affiliation: Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brasil.
authors.forename: Débora Matias
authors.initials: DM
authors.lastname: Oliveira
authors.affiliation: Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brasil.
authors.forename: Beatriz Pires
authors.initials: BP
authors.lastname: Ferreira
authors.affiliation: Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brasil.
authors.forename: Elisabete Aparecida Mantovani Rodrigues de
authors.initials: EA
authors.lastname: Resende
authors.affiliation: Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brasil.
authors.forename: Heloísa Marcelina Cunha
authors.initials: HM
authors.lastname: Palhares
mesh_terms: D000365:Age Determination by Skeleton; D001827:Body Height / Q000187:drug effects*; D001938:Brazil; D002648:Child; D002675:Child, Preschool; D004958:Estradiol / Q000097:blood; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D043373:Follicle Stimulating Hormone, Human / Q000097:blood; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives*; D006801:Humans; D007223:Infant; D016729:Leuprolide / Q000627:therapeutic use*; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D011629:Puberty, Precocious / Q000097:blood / Q000188:drug therapy*; D012189:Retrospective Studies; D013739:Testosterone / Q000097:blood; D016896:Treatment Outcome
chemical_list: D005300:Fertility Agents, Female; D043373:Follicle Stimulating Hormone, Human; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D004958:Estradiol; D007986:Luteinizing Hormone; D016729:Leuprolide